- Home
- INZY
INZY
Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 256.3M | IPO Year: | 2020 |
| Target Price: | $15.22 | AVG Volume (30 days): | 989.2K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $6.24 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Inozyme Pharma Inc. News
INZY Breaking Stock News: Dive into INZY Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
Zacks
a month ago
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
TipRanks
2 months ago
Biotech Alert: Searches spiking for these stocks today
Zacks
2 months ago
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
MT Newswires
2 months ago
Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23
MT Newswires
2 months ago
TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4
MT Newswires
2 months ago
Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform
MT Newswires
2 months ago
Needham Downgrades Inozyme Pharma to Hold From Buy
Compare INZY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INZY Inozyme Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.